Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 7/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291137 | 0.81 | PDE7A (1.00) | PDE7AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL300108 | 0.81 | PDE7A (1.00) | PDE7AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL30837930 | 0.81 | PDE7A (1.00) | PDE7AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL19487245 | 0.81 | LMNA (0.77) | PDE7AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL290063 | 0.78 | PDE7A (0.67) | PDE7AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL30837910 | 0.78 | PDE7A (0.67) | PDE7AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL9972171 | 0.73 | LMNA (0.74) | PDE7ASMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL9299483 | 0.73 | PDE7A (0.51) | PDE7AMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL1101917 | 0.72 | LMNA (0.72) | PDE7AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1101909 | 0.72 | LMNA (0.72) | PDE7AMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192610-B2 | Use of quinazoline derivatives for neurodegenerative diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-11-24 | — | — | US | claimed |
| EP-2433637-B9 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2015-06-10 | — | — | EP | claimed |
| EP-2433637-B1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2014-06-11 | — | — | EP | claimed |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-05-24 | — | — | US | claimed |
| EP-2433637-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-03-28 | — | — | EP | claimed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-11464785-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2012-05-10 | — | — | US | disclosed |
| EP-2433637-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-03-28 | — | — | EP | disclosed |
| EP-2427193-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885MEN1 3007/4885KMT2A 786/4885 |
| US-11464785-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885MEN1 3007/4885KMT2A 786/4885 |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885MEN1 409/4885KMT2A 3973/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | PDE7A 10/4885MEN1 3007/4885KMT2A 786/4885 |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE7A 3/4885MEN1 3873/4885KMT2A 1939/4885 |
| US-20120129877-A1 | USE OF QUINAZOLINE DERIVATIVES FOR NEURODEGENERATIVE DISEASES | PARK7, SNCA, NLN | PDE7A 867/4885MEN1 3015/4885KMT2A 2468/4885 |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PDE4B, PDE7B, PDE12 | PDE7A 6/4885MEN1 2199/4885KMT2A 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.